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Abstract
Purpose: Radiation therapy in low and high doses is known to be associated with the occurrence of late secondary sarcomas.
The addition of chemotherapy has not been clearly demonstrated as a contributing factor. We describe three patients with
radiation-associated leiomyosarcoma who had also received antimetabolite chemotherapy.
Methods: Three cases of leiomyosarcoma occurring 9–27 years after radiation and antimetabolite chemotherapy are
presented, along with histopathological details. A Medline search was used to assess prior reports of leiomyosarcoma after
radiation.
Results: These three cases appear to be the first reported in which leiomyosarcoma followed therapy with radiation and
antimetabolites.
Discussion: With the increasing use of antimetabolite therapy combined with radiation, there is the potential for more
occurrences of leiomyosarcoma or other post-treatment sarcomas.
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Introduction
There is a clear association between radiotherapy
and an increased risk of development of secondary
solidtumors,includingsarcomas.
1–11Patientstreated
with radiotherapy (RT) for Hodgkin’s disease have a
risk as high as 20% at 20 years, and much of this
excess risk is attributable to radiotherapy with
or without chemotherapy.
12,13 Therapeutic radiation
for other malignant and benign diseases has also been
associated with secondary malignancies, includ-
ing secondary sarcomas.
14,17 Numerous histological
subtypes of secondary sarcoma have been reported,
but the most common have been osteosarcoma,
fibrosarcoma, malignant fibrous histiocytoma
(MFH), and angiosarcoma. Leiomyosarcoma (LMS)
has been reported to occur after radiotherapy, but
mostly in single case reports, and several very small
series. These LMS have occurred in diverse sites,
after 6–35 years, and after treatment for a variety of
malignancies.
18–42
In this report, we describe a series of three patients
who developed leiomyosarcoma in the field of
therapeutic radiation after 9–27 years. All had also
been treated with antimetabolite chemotherapy.
Patients and methods
We performed a Medline search encompassing the
dates 1966–2001. Search terms were used to link
radiation therapy, chemotherapy, antimetabolites,
and Hodgkin’s disease to secondary malignan-
cies, solid tumors, sarcoma, and leiomyosarcoma.
Reports of radiation-associated leiomyosarcoma
were reviewed for elapsed time between RT and
secondary leiomyosarcoma, as well as association of
chemotherapy with RT. The cases are summarized
in Table 1.
Case reports and results
Case 1
A 71-year-old man was treated in 1984 for rectal
cancer with a low anterior resection and post-
operative 5-fluorouracil, together with radiotherapy
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resected in 1990. He developed a spontaneous
pneumothorax in September 1998, which recurred
after chest tube evacuation. A CXR and subsequent
chest CT scan showed bilateral pulmonary nodules.
A thoracoscopic biopsy revealed a high-grade leio-
myosarcoma (Fig. 1). The patient had a 1-year
history of posterior thigh and buttock pain; clinical
examination demonstrated a large deep left buttock
mass. CT scan demonstrated the primary tumor
as an 8 5 4-cm mass deep to the left gluteal
muscles, and a 6-cm ring enhancing collection
posterior to the rectum.
Case 2
A 60-year-old man had a 30-year history of relaps-
ing ‘midline destructive disease’ and an acoustic
neuroma diagnosed in 1995. Aggressive disease over
the years resulted in disease-related and surgical loss
of nasal and facial bone and cartilage. Extensive past
treatment included antibiotics, cyclophosphamide,
azathioprine, and multiple surgical procedures. He
received radiation to the midline face in 1971
(2100cGy Cobalt radiation) and again in 1984
(4500cGy; the exact timing of the azathioprine and
cyclophosphamide in relationship to the two courses
(a) (b)
Fig. 1. (a) Low power H&E stain reveals a diffusely elongated spindle cell neoplasm from a 1.5-cm tumor. (b) Representative high
power view of immunostain for smooth muscle antigen (SMA). Additional stains for desmin, muscle specific antigen, keratin, HMB45,
and S100 were negative.
Table 1. Summary of cases
Pt. Initial
tumor
Initial treatment Prior RT Second primary Comments
Date Dose
(Gy)
Date Site
1 Rectum RT
5-Fluorouracil
1984 50.4 1998 (14 years) Buttock LTFU
2 Face RT 1971 21 1998 Maxillary Doxorubicin þ
Cyclophosphamide
azathioprine
1984 45 (14/27 years) sinus Ifosfamide!
Surgery!NED
3 Larynx RT 5-Fluorouracil, hydroxyurea 1989 60 1998 (9 years) Trachea Doxorubicinþ
dacarbazine!Died
ALL RT plus antimetabolite 9–27-year interval
LTFU, lost to follow-up; NED, no evidence of disease; RT, radiotherapy; Gy gray.
168 B. Brockstein et al.of radiation is not known). In June 1998 he noted a
small mass beneath the left eye. A work-up included
a CT scan of the sinuses, which showed a large mass
involving the left face in the area of the left maxillary
sinus with extensive destruction of the adjacent bony
structures and extension into the ethmoid and
sphenoid sinuses. A biopsy in October 1998 revealed
a high-grade leiomyosarcoma (Fig. 2). The patient
had a dramatic response to three cycles of pre-
operative doxorubicin and ifosfamide. Surgical
excision of the tumor revealed only microscopic
deposits of residual LMS. Two additional cycles of
chemotherapy were given, and the patient remained
free of disease 1 year later.
Case 3
A 76-year-old woman was treated for a T2N0M0
squamous cell carcinoma of the epiglottis in 1989
with laser excision and post-operative infusional
5-FU (800mg/m
2per day 5 days every other week
for six cycles), oral hydroxyurea (1000 twice daily
for 5.5 days, every other week for six cycles) and
radiation (6000cGy). In October 1998, the patient
presented with dysphagia and stridor; direct laryngos-
copy and CT scanning revealed a large, partially
obstructing tracheal mass (Fig. 3). A tracheal stent
was placed, and a biopsy revealed a high-grade
leiomyosarcoma (Fig. 4). The mass was unresect-
able, and she underwent palliative chemotherapy
with doxorubicin and dacarbazine in November
1998. She tolerated the chemotherapy well but died
within a month of disease progression.
Discussion
We report three cases of radiation associated LMS
occurring 9–14 years following RT (or 9–27, as
one patient received two separate courses of RT) in
three patients who presented to our clinic in the
same month. All had received prior antimetabolite
therapy: in one case, 5-fluorouracil; in another
azathioprine; and in the third, 5-fluorouracil and
hydroxyurea. One of these patients also received the
alkylating agent cyclophosphamide.
Clear associations have been made between
therapeutic RT for cancer and the development of
late second malignancies.
1–7 These associations have
also been made for low-dose RT as used in the past
for benign conditions such as tonsillar enlargement,
menorrhagia, peptic ulcer disease or acne.
8–10 An
excess of hematological malignancies and solid
tumors occur above that expected for either age-
matched controls or disease-matched controls not
receiving radiation. Even though soft tissue sarcomas
represent only a small percentage of these solid
tumors, the excess relative risk at 20 years has been
reported to be six- to several hundred-fold greater
than expected.
2,6,11 Whereas there appears to be a
plateau in the incidence of hematological malig-
nancies at 10 years, the peak solid tumor incidence
has not been identified, and series with 15–20 year
(a) (b)
Fig. 2. (a) High power H&E stain reveals a pleomorphic high-grade spindle cell neoplasm. (b) Representative high power
view of immunostain for SMA. SMA, as well as muscle specific antigen, is clearly positive in pleomorphic malignant tumor cells.
Desmin and Leukocyte common antigen were negative, and S100 and keratin showed occasional positivity. (LMS may occasionally
show keratin positivity.)
RT-induced LMS: control of antimetabolites 169Fig. 3. CT of neck with intravenous contrast shows tracheal mass growing through tracheal ring stent.
(a) (b)
Fig. 4. (a) High power H&E reveals a spindle cell neoplasm with marked nuclear atypia and abnormal mitotic figures.
(b) High power SMA stain supports the diagnosis of leiomyosarcoma. Additional stains included vimentin (positive) and
keratin (negative).
170 B. Brockstein et al.follow-up report a total incidence as high as over
20%.
1,3,5,11,12
Chemotherapy clearly contributes to the develop-
ment of secondary hematological malignancies but
not as clearly to the development of secondary solid
tumors. Lung cancer risk is likely increased by
chemotherapy,
2 whereas breast cancer risk appears
to be more related to RT than chemotherapy.
1,13
In several series reporting post-radiation or radiation-
associated sarcomas, the most common subtypes
have been angiosarcoma, osteosarcoma, fibrosar-
coma, and MFH.
10,15–17 Leoimyosarcoma has not
been commonly reported. We were able to find 33
reports of RT associated LMS in the English
language literature, comprising 21 single case
reports,
18–38 four series of two patients
16,39–41 and
one series of four patients.
10 These 33 leiomyosar-
comas occurred 6–35 years after therapeutic RT for
a variety of benign and malignant diseases. In the
largest series, none of the four patients had received
chemotherapy, although several other cases have
been reported in association with chemotherapy,
mostly alkylating agents. The prognosis for patients
with post-radiation solid tumors, and sarcomas in
particular, is poor.
16,42,43
All three of our cases of radiation-associated LMS,
which occurred 9–27 years after RT, presented to
our clinic in the same month. All had received prior
antimetabolite therapy: in two cases 5-fluorouracil,
and in one case azathioprine. It is possible that
antimetabolite therapy leads to mis-incorporation of
nucleotides or other faulty DNA repair in the setting
of RT induced sublethal damage, allowing for later
sarcomagenesis in otherwise vulnerable smooth
muscle cells. Prior reports of secondary sarcomas
have not reported the association of antimetabolite
therapy as a contributory factor. There is, however, a
long latency period from radiotherapy to second
primary sarcoma, so the rise in excess cases may lag
behind any increase in antimetabolite plus radio-
therapy use. With the increasing evidence for the use
of 5-FU as a radiosensitizer in the treatment of
malignancies, such as head and neck cancer, cervical
cancer, stomach cancer, rectal cancer, and pan-
creatic cancer, more such cases may be seen in the
future.
Conclusions
Leiomyosarcoma may rarely occur as a radiation-
induced or associated malignancy. In our series of
three patients, LMS occurred late after radiotherapy
and all had received antimetabolites either concomi-
tant with RT or close to the time of RT. This
association has not been previously reported, but
there may be a lag time between the increasing use of
treatment with RT plus antimetabolite and the
development of LMS.
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